The ALTTO trial is the largest adjuvant study ever conducted in the field of HER2-positive early breast cancer and, including at least 5-year follow-up data from all patients9, represented a unique opportunity to investigate the reliability and prognostic performance of PREDICT in women with HER2-positive disease. This evidence concerns the gene ERBB2 and breast carcinoma.